{
    "Trade/Device Name(s)": [
        "XPER Technology PREMIUM Pro Blood Glucose Monitoring System",
        "XPER Technology PREMIUM Pro Blood Glucose Meter",
        "XPER Technology PREMIUM Pro Blood Glucose Test Strips",
        "TaiDoc Blood Glucose Control Solutions"
    ],
    "Submitter Information": "TaiDoc Technology Corporation",
    "510(k) Number": "K221349",
    "Predicate Device Reference 510(k) Number(s)": [
        "K200788"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PZI"
    ],
    "Summary Letter Date": "March 11, 2024",
    "Summary Letter Received Date": "March 11, 2024",
    "Submission Date": "November 18, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [
        "Single-use, auto-disabling lancing device"
    ],
    "Instrument(s)/Platform(s)": [
        "XPER Technology PREMIUM Pro Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric detection",
        "Electrochemical biosensor",
        "FAD-GDH enzyme-based chemistry"
    ],
    "Methodologies": [
        "Quantitative glucose measurement",
        "Biosensor technology"
    ],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for TaiDoc XPER Technology PREMIUM Pro Blood Glucose Monitoring System for point-of-care quantitative glucose measurement using amperometric biosensor technology.",
    "Indications for Use Summary": "Intended for point-of-care, in vitro diagnostic, multiple-patient use for quantitative determination of glucose in fresh capillary whole blood from fingertips in endocrinology clinic laboratories and physician office laboratories; not for diabetes diagnosis, neonatal, acute care, nursing or hospital settings, or patients receiving intensive medical intervention.",
    "fda_folder": "Clinical Chemistry"
}